Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Rabbit Anti-FGFR3 Recombinant Antibody (CBXF-1160) (CBMAB-F0874-CQ)

Online Inquiry

Summary

Host Animal
Rabbit
Specificity
Human, Mouse, Rat
Clone
CBXF-1160
Antibody Isotype
IgG
Application
WB

Basic Information

Specificity
Human, Mouse, Rat
Antibody Isotype
IgG
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Fibroblast Growth Factor Receptor 3
Introduction
This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia.
Entrez Gene ID
Human2261
Mouse14184
Rat84489
UniProt ID
HumanP22607
MouseQ61851
RatF1LSN4
Alternative Names
Fibroblast Growth Factor Receptor 3; EC 2.7.10.1; FGFR-3; JTK4; Fibroblast Growth Factor Receptor 3 Variant 4; Achondroplasia, Thanatophoric Dwarfism; Hydroxyaryl-Protein Kinase; Tyrosine Kinase JTK4;
Function
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling.
Biological Process
Bone maturation Source: BHF-UCL
Bone mineralization Source: BHF-UCL
Bone morphogenesis Source: BHF-UCL
Cell-cell signaling Source: Ensembl
Chondrocyte differentiation Source: UniProtKB
Chondrocyte proliferation Source: UniProtKB
Endochondral bone growth Source: UniProtKB
Endochondral ossification Source: UniProtKB
Fibroblast growth factor receptor apoptotic signaling pathway Source: UniProtKB
Fibroblast growth factor receptor signaling pathway Source: UniProtKB
MAPK cascade Source: ProtInc
Negative regulation of developmental growth Source: BHF-UCL
Peptidyl-tyrosine phosphorylation Source: UniProtKB
Positive regulation of cell population proliferation Source: UniProtKB
Positive regulation of ERK1 and ERK2 cascade Source: UniProtKB
Positive regulation of kinase activity Source: GO_Central
Positive regulation of MAPK cascade Source: UniProtKB
Positive regulation of phosphatidylinositol 3-kinase activity Source: UniProtKB
Positive regulation of phospholipase activity Source: UniProtKB
Positive regulation of tyrosine phosphorylation of STAT protein Source: UniProtKB
Protein autophosphorylation Source: UniProtKB
Skeletal system development Source: ProtInc
Transmembrane receptor protein tyrosine kinase signaling pathway Source: GO_Central
Cellular Location
Isoform 1: Endoplasmic reticulum; Cell membrane; Cytoplasmic vesicle. The activated receptor is rapidly internalized and degraded. Detected in intracellular vesicles after internalization of the autophosphorylated receptor.
Isoform 2&4: Cell membrane
Isoform 3: Secreted
Involvement in disease
Achondroplasia (ACH):
A frequent form of short-limb dwarfism. It is characterized by a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands. ACH is an autosomal dominant disease.
Crouzon syndrome with acanthosis nigricans (CAN):
Classic Crouzon disease which is caused by mutations in the FGFR2 gene is characterized by craniosynostosis (premature fusion of the skull sutures), and facial hypoplasia. Crouzon syndrome with acanthosis nigricans (a skin disorder characterized by pigmentation anomalies), CAN, is considered to be an independent disorder from classic Crouzon syndrome. CAN is characterized by additional more severe physical manifestation, such as Chiari malformation, hydrocephalus, and atresia or stenosis of the choanas, and is caused by a specific mutation (Ala-391 to Glu) in the transmembrane domain of FGFR3. It is proposed to have an autosomal dominant mode of inheritance.
Thanatophoric dysplasia 1 (TD1):
A neonatal lethal skeletal dysplasia. Affected individuals manifest severe shortening of the limbs with macrocephaly, narrow thorax, short ribs, and curved femurs.
Thanatophoric dysplasia 2 (TD2):
A neonatal lethal skeletal dysplasia causing severe shortening of the limbs, narrow thorax and short ribs. Patients with thanatophoric dysplasia type 2 have straight femurs and cloverleaf skull.
Hypochondroplasia (HCH):
Autosomal dominant disease and is characterized by disproportionate short stature. It resembles achondroplasia, but with a less severe phenotype.
Bladder cancer (BLC):
A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
Cervical cancer (CERCA):
A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.
Camptodactyly, tall stature, and hearing loss syndrome (CATSHLS):
An autosomal dominant syndrome characterized by permanent and irreducible flexion of one or more fingers of the hand and/or feet, tall stature, scoliosis and/or a pectus excavatum, and hearing loss. Affected individuals have developmental delay and/or mental retardation, and several of these have microcephaly. Radiographic findings included tall vertebral bodies with irregular borders and broad femoral metaphyses with long tubular shafts. On audiological exam, each tested member have bilateral sensorineural hearing loss and absent otoacoustic emissions. The hearing loss was congenital or developed in early infancy, progressed variably in early childhood, and range from mild to severe. Computed tomography and magnetic resonance imaging reveal that the brain, middle ear, and inner ear are structurally normal.
Multiple myeloma (MM):
A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.
Lacrimo-auriculo-dento-digital syndrome (LADDS):
An autosomal dominant ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Lacrimo-auriculo-dento-digital syndrome is characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.
Keratinocytic non-epidermolytic nevus (KNEN):
Epidermal nevi of the common, non-organoid and non-epidermolytic type are benign skin lesions and may vary in their extent from a single (usually linear) lesion to widespread and systematized involvement. They may be present at birth or develop early during childhood.
Muenke syndrome (MNKS):
A condition characterized by premature closure of coronal suture of skull during development (coronal craniosynostosis), which affects the shape of the head and face. It may be uni- or bilateral. When bilateral, it is characterized by a skull with a small antero-posterior diameter (brachycephaly), often with a decrease in the depth of the orbits and hypoplasia of the maxillae. Unilateral closure of the coronal sutures leads to flattening of the orbit on the involved side (plagiocephaly). The intellect is normal. In addition to coronal craniosynostosis some affected individuals show skeletal abnormalities of hands and feet, sensorineural hearing loss, mental retardation and respiratory insufficiency.
Keratosis, seborrheic (KERSEB):
A common benign skin tumor. Seborrheic keratoses usually begin with the appearance of one or more sharply defined, light brown, flat macules. The lesions may be sparse or numerous. As they initially grow, they develop a velvety to finely verrucous surface, followed by an uneven warty surface with multiple plugged follicles and a dull or lackluster appearance.
Testicular germ cell tumor (TGCT):
A common malignancy in males representing 95% of all testicular neoplasms. TGCTs have various pathologic subtypes including: unclassified intratubular germ cell neoplasia, seminoma (including cases with syncytiotrophoblastic cells), spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.
Achondroplasia, severe, with developmental delay and acanthosis nigricans (SADDAN):
A severe form of achondroplasia associated with developmental delay and acanthosis nigricans. Patients manifest short-limb dwarfism, with a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands. Acanthosis nigricans is a skin condition characterized by brown-pigmented, velvety verrucosities in body folds and creases.
Topology
Extracellular: 23-375
Helical: 376-396
Cytoplasmic: 397-806
PTM
Autophosphorylated. Binding of FGF family members together with heparan sulfate proteoglycan or heparin promotes receptor dimerization and autophosphorylation on tyrosine residues. Autophosphorylation occurs in trans between the two FGFR molecules present in the dimer. Phosphorylation at Tyr-724 is essential for stimulation of cell proliferation and activation of PIK3R1, STAT1 and MAP kinase signaling. Phosphorylation at Tyr-760 is required for interaction with PIK3R1 and PLCG1.
Ubiquitinated. Is rapidly ubiquitinated after ligand binding and autophosphorylation, leading to receptor internalization and degradation. Subject to both proteasomal and lysosomal degradation.
N-glycosylated in the endoplasmic reticulum. The N-glycan chains undergo further maturation to an Endo H-resistant form in the Golgi apparatus.
More Infomation

Loeffler, C. M. L., Bruechle, N. O., Jung, M., Seillier, L., Rose, M., Laleh, N. G., ... & Kather, J. N. (2022). Artificial Intelligence–based Detection of FGFR3 Mutational Status Directly from Routine Histology in Bladder Cancer: A Possible Preselection for Molecular Testing?. European urology focus, 8(2), 472-479.

Gött, H., & Uhl, E. (2022). FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma. International Journal of Molecular Sciences, 23(15), 8675.

Kimura, T., Bosakova, M., Nonaka, Y., Hruba, E., Yasuda, K., Futakawa, S., ... & Krejci, P. (2021). An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice. Science Translational Medicine, 13(592), eaba4226.

Zengin, Z. B., Chehrazi-Raffle, A., Salgia, N. J., Muddasani, R., Ali, S., Meza, L., & Pal, S. K. (2021, November). Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. In Urologic Oncology: Seminars and Original Investigations. Elsevier.

van Rhijn, B. W., Mertens, L. S., Mayr, R., Bostrom, P. J., Real, F. X., Zwarthoff, E. C., ... & Zuiverloon, T. C. (2020). FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment?. European Urology, 78(5), 682-687.

Kacew, A., & Sweis, R. F. (2020). FGFR3 alterations in the era of immunotherapy for urothelial bladder cancer. Frontiers in Immunology, 11, 575258.

Chew, N. J., Nguyen, E. V., Su, S. P., Novy, K., Chan, H. C., Nguyen, L. K., ... & Daly, R. J. (2020). FGFR3 signaling and function in triple negative breast cancer. Cell Communication and Signaling, 18(1), 1-17.

Long, X., Shi, Y., Ye, P., Guo, J., Zhou, Q., & Tang, Y. (2020). MicroRNA-99a suppresses breast cancer progression by targeting FGFR3. Frontiers in oncology, 9, 1473.

Li, L., Zhang, S., Li, H., & Chou, H. (2019). FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR. BMC cancer, 19(1), 1-12.

Kawane, T., Qin, X., Jiang, Q., Miyazaki, T., Komori, H., Yoshida, C. A., ... & Komori, T. (2018). Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3. Scientific reports, 8(1), 1-17.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Rabbit Anti-FGFR3 Recombinant Antibody (CBXF-1160)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Online Inquiry